Canada markets closed

Seelos Therapeutics, Inc. (SEEL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3393+0.0103 (+3.13%)
At close: 04:00PM EDT
0.3600 +0.02 (+6.10%)
After hours: 07:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3290
Open0.3420
Bid0.2437 x 200
Ask0.4452 x 200
Day's Range0.3300 - 0.3550
52 Week Range0.2700 - 49.8000
Volume251,101
Avg. Volume441,398
Market Cap5.635M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-7.7300
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est120.00
  • PR Newswire

    Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on the current discussions of potential partnerships and collaborations and announced the appointment of Richard Pascoe as Chairman of the Board of Directors of Seelos to lead the ongoing strategic process and business development discussions and negotiations. Mr. Pascoe has served

  • Reuters

    UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study

    Seelos Therapeutics' experimental ALS drug did not meet the main goal of a mid-stage trial, the company said on Tuesday, the latest study setback in a field littered with clinical failures. The drug, SLS-005, when tested in 120 patients, failed to show statistically significant improvement in motor function and reducing mortality in patients with ALS, or amyotrophic lateral sclerosis, versus a placebo. ALS affects 16,000 to 32,000 people in the United States, and has long eluded researchers searching for an effective treatment.

  • PR Newswire

    Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in caring for the ALS community. Their unique and innovative approach continues